Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.
November 2005 in “The Journal of Urology” Dutasteride may lower the chance of finding prostate cancer in men with enlarged prostates.
August 2021 in “Journal of the American Academy of Dermatology” Oral baricitinib is effective and safe for treating alopecia areata.
February 2006 in “PubMed” Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.
3 citations
,
August 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” The DNN-DTIs method accurately predicts drug-target interactions and is useful for drug repositioning.
1 citations
,
June 2018 in “International Journal of Dermatology” DNCB is highly effective for treating alopecia areata with minimal long-term side effects.
November 2024 in “Advances in Pharmacology and Pharmacy” A reliable method was developed to measure Minoxidil and Tofacitinib in gel for hair loss treatment.
March 2016 in “The Journal of Urology” The discovery of 5α-reductase deficiency in guevedoces led to the development of important urologic medications.
September 2023 in “Journal of The American Academy of Dermatology” Baricitinib treatment can help regrow scalp hair and eyebrows or eyelashes in people with severe alopecia areata.
July 2013 in “Edinburgh Research Archive (University of Edinburgh)” Dutasteride may reduce insulin sensitivity and increase body fat.
January 2019 in “Dermatologica Sinica” Dutasteride improved both hair loss and acne in two young men.
March 2017 in “Fundamental & Clinical Pharmacology” The model and estimator can predict drug exposure in kidney transplant patients well.
14 citations
,
August 2007 in “Bioorganic & Medicinal Chemistry Letters” The compound (1R,2S)-4-(2-Cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile can stimulate hair growth and reduce oil production when applied topically.
Baricitinib effectively promotes hair regrowth in severe alopecia with minimal side effects.
24 citations
,
June 2013 in “Expert opinion on pharmacotherapy” Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.
Dupilumab helped improve skin and prevent new lesions in a child with a rare immune disorder and severe eczema.
1 citations
,
January 2016 in “Klinicheskaya dermatologiya i venerologiya” May 2025 in “Journal of the European Academy of Dermatology and Venereology”
5 citations
,
January 1998 in “Journal of Toxicologic Pathology” Maneb causes delayed hair follicle damage in rats.
7 citations
,
March 2022 in “Molecules” 5-Bromo-3,4-dihydroxybenzaldehyde could potentially help hair growth by activating certain cell pathways and inhibiting others.
27 citations
,
May 2015 in “Neuropharmacology” Dutasteride protects dopamine neurons in Parkinson's mice, but Finasteride doesn't.
February 2026 in “PubMed” Rutin may help regrow hair by stabilizing β-catenin and blocking GSK3β.
2 citations
,
August 2020 in “JCRPE” A girl with Denys-Drash syndrome was misdiagnosed due to biotin affecting her hormone test results.
March 2021 in “CRC Press eBooks” Mesotherapy involves injecting substances like dutasteride, minoxidil, and vitamins into the skin to treat hair loss and skin conditions, with good patient satisfaction but possible skin inflammation.
January 2025 in “Skin Health and Disease” Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
15 citations
,
February 2019 in “Journal of clinical medicine” Atorvastatin reversed memory problems caused by cancer drug trastuzumab and improved its cancer-fighting abilities without causing hair loss.
July 2025 in “Clinical Medicine” Oral betamethasone works faster than oral tofacitinib for hair regrowth in alopecia areata.
3 citations
,
February 2022 in “Rheumatology” Baricitinib was effective in treating a patient with dermatomyositis and hair loss.
1 citations
,
September 2024 in “Journal of the American Academy of Dermatology”
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.